kinase 3 (WNK3) is a member of a subfamily of serine/threonine kinases that modulate the activity of the electroneutral cation-coupled chloride cotransporters. WNK3 activates NKCC1/2 and NCC and inhibits the KCCs. Four splice variants are generated from the WNK3 gene. Our previous studies focused on the WNK3-18a variant. However, it has been suggested that other variants could have different effects on the cotransporters. Thus, the present study was designed to define the effects of all WNK3 variants on members of the SLC12 family. By RT-PCR from a fetal brain library, exons 18b and 22 were separately amplified and subcloned into the original WNK3-18a or catalytically inactive WNK3-D294A to obtain all four potential combinations with and without catalytic activity (18a, 18aϩ22, 18b, and 18bϩ22). The basal activity of the cotransporters and the effects of WNK3 isoforms were assessed in Xenopus laevis oocytes coinjected with each of the WNK3 variant cRNAs. In isotonic conditions, the basal activity of NCC and NKCC1/2 were increased by coinjection with any of the WNK3. The positive effects occurred even in hypotonic conditions, in which the basal activity of NKCC1 is completely prevented. Consistent with these observations, when expressed in hypotonicity, all KCCs were active, but in the presence of any of the WNK3 variants, KCC activity was completely reduced. That is, NKCC1/2 and NCC were inhibited, even in hypertonicity, while KCCs were activated, even in isotonic conditions. We conclude that the effects of all WNK3 variants toward SLC12 proteins are similar.
ϩ -coupled chloride (NKCC1/2 and NCC) and K ϩ -coupled chloride (KCC1-4) cotransporters, which encompass two branches of the SLC12 gene family of solute transporters (12) . Under hypotonic conditions, cell volume increases because water enters the cell. In this state, the coordinated activation of KCCs and inhibition of NKCCs helps to return the cell volume to normal by increasing Cl Ϫ exit along with water. Under hypertonic conditions, cell volume decreases because water leaves the cell, and to reestablish cell volume, KCCs are inhibited while NKCCs are activated. In this way, the cell increases chloride entry along with water. Given that the long-term activity of SLC12 cotransporters changes the intracellular chloride concentration [ Cl Ϫ ] i , the coordinated function of these cotransporters is also important for essential neurological functions because the way that postsynaptic cells respond to neurotransmitters that act on chloride channel-coupled receptors, such as ␥-aminobutyric acid (GABA), is defined by [Cl Ϫ ] i (11) . Finally, the activity of the SLC12 cotransporters is also important to the regulation of transcellular ion transport in many epithelial cells, including the nephron, and thus is critical for blood pressure control (4) .
The K ϩ -Cl Ϫ cotransporters move chloride outside the cell, are inhibited by phosphorylation, and are activated by dephosphorylation. In contrast, the Na ϩ -K ϩ -2Cl Ϫ cotransporters introduce chloride into the cell, are inhibited by dephosphorylation, and are activated by phosphorylation (4) . It has been proposed that KCCs/NKCCs must be tightly regulated by cell volume and/or [Cl Ϫ ] i by a kinase/phosphatase pair. We have shown that with-no-lysine kinase 3 (WNK3) possesses several properties that suggest it could be the Cl Ϫ /volume-sensitive regulatory kinase that, in association with protein phosphatases, reciprocally modifies the phosphorylation/dephosphorylation states of the SLC12 proteins and thus their activities (for review, see Ref. 10 ). WNK3 activates NKCCs by increasing their phosphorylation, even when cells are incubated in hypotonic medium, where normally they are inactivated (9, 10, 20, 21) . In contrast, the coexpression of KCCs with WNK3 completely inhibits KCC function, even when cells are exposed to a hypotonic medium, in which the KCCs are normally active and dephosphorylated (2, 22) . Interestingly, due to a D294A substitution, the catalytically inactive form of WNK3 not only loses its activating and inhibitory properties against the NKCCs and KCCs, respectively, but acquires the opposite properties. WNK3-D294A becomes a potent inhibitor of the Na ϩ -coupled chloride cotransporters, inducing dephosphorylation even in hypertonic conditions in which NKCCs are activated, while it becomes a potent activator of KCCs, even in isotonic conditions in which they are usually inactive (2, 9, 10, 21) . Under isotonic conditions, activation of the KCCs by the kinase-dead WNK3 can be reversed by calyculin or cyclosporine, implying the involvement of protein phosphatases in the process.
Four WNKs have been identified, two of which when mutated (WNK1 and WNK4) cause a form of salt-sensitive hypertension in humans known as pseudohypoaldosteronism type II or familial hyperkalemic hypertension (30) . The mechanism by which WNKs affect blood pressure is, at least in part, due to their ability to modulate the activity of the renal thiazide-sensitive Na ϩ -Cl Ϫ cotransporter, NCC (5, 6). As indicated above, WNK3 is an activator and WNK3-D294A is an inhibitor of NCC (21) . In addition to several epithelial tissues, WNK3 is present in the brain, in which it is coexpressed with NKCC1/KCC2 in GABAergic neurons (9) , positioning it as an important kinase for modulating neuronal activity. The WNK3 gene encodes four putative alternatively spliced variants that are generated by the combination of two mutually exclusive exons 18 (18a and 18b), with the presence or absence of exon 22. As shown in Fig. 1 , the potential isoforms are WNK3-18a, WNK3-18b, WNK3-18aϩ22, and WNK3-18bϩ22. Interestingly, exon 18b appears to be exclusively expressed in the central nervous system (CNS), while WNK3-18a is present in epithelial tissues (8) . All functional studies discussed above were performed using the WNK3-18a epithelial variant (2, 9, 10, 21) . However, a recent study suggested that the effects of WNK3-18a and WNK3-18b toward NCC are opposite; that is, activation by WNK3-18a and inhibition by WNK3-18b (7). This observation is probably irrelevant to NCC, because WNK18-b is not present in the kidney and NCC is not expressed in the CNS. However, if the WNK3-18a and WNK3-18b isoforms also produce opposite effects in the SLC12 members present in the CNS, these variants could represent a key regulatory kinase system for the excitability of GABAergic neurons. Thus, the present study was designed to investigate the functional differences of the four potential WNK3 variants on all members of the SLC12 gene family.
MATERIALS AND METHODS

Clones, Cloning, and Sequencing
The human WNK3 cDNA clone containing exon 18a without exon 22 (isoform 3) used in this study was previously described (9, 21) . A fragment of WNK3 containing the 18b exon was amplified from a human fetal brain cDNA library (Clontech) using the Expand High Fidelity Plus PCR System (Roche) and pasted into the original human WNK3 cDNA isoform 3. To this end, custom primers were designed beyond the unique restriction sites Stu I and Dra III flanking exon 18 of WNK3 cDNA. The amplified fragment was digested with Stu I and Dra III and pasted into WNK3 cDNA. Several cDNA colonies were obtained, and clones containing exon 18a or 18b were identified by automatic DNA sequencing. Then, by double-step PCR, the exon 22 sequence was inserted into both 18a and 18b cDNA clones. To obtain exon 22, double-step PCR was performed using the WNK3 cDNA as template with the primers forward 5=-TCCTCAGATGCTTC-ACTTCCA-3= and reverse 5=-ATTTTCCAACTCATTTATAA-GGCAGCTTTTCCCTGTAGCAACTATGCCATTGTCCACATGT-GTC-3= to amplify fragment A-B (1,188 and 1,325 bp) and the primers forward 5=-GGGAAAAGCTGCCTTATAAATGAGTTGGAAAA-TCCACTGTGTGTGGAGAGTAATGCAGCATCATGC-3= and reverse 5=-GTGTAAGTTGGTATTATG-3= to amplify fragment C-D (759 and 793 bp). The second round of PCR was done using purified fragments A-B and C-D as templates, with external primers forward 5=-TCCTCAGATGCTTCACTTCCA-3= and reverse 5=-GTGTAAGTTG-GTATTATG-3=(1,947 and 2,118 bp) to obtain the A-D fragment containing exon 22. With a cut and paste, this fragment was inserted into the original WNK3 cDNA harboring exon 18a or 18b. All the amplified fragments were sequenced to rule out unwanted mutations. Finally, the exon 18b and exon 22 cDNA fragments were also inserted into human WNK3 cDNA in which aspartate 294 had previously been substituted to alanine (D294A) to render WNK3 catalytically inactive (9, 21) .
The following cDNA clones of the SLC12A family used in this study were previously reported: NCC (3), NKCC1 (9), NKCC2 (3), KCC1 and KCC4 (17), KCC2b (24), KCC3a and KCC3b (18) . KCC2a (26) was obtained by cutting and pasting KCC2 exon 1a amplified from the human fetal brain cDNA library in a process similar to that described above. KCC2a construction was verified by DNA sequencing.
In Vitro cRNA Translation
To prepare cRNA for microinjection, each of the wild-type or mutant cDNAs was linearized at the 3=-end with Not I, Nhe I, or Xba I from New England Biolabs (Carlsbad, CA) and transcribed in vitro, using the T7 RNA polymerase mMESSAGE mMACHINE (Ambion, Austin, TX) transcription system. cRNA product integrity was confirmed on agarose gels. cRNA concentration was determined by the absorbance reading at 260 nm (DU 640, Beckman, Fullerton, CA). cRNAs were stored in aliquots at Ϫ80°C until use.
Preparation of Xenopus laevis Oocytes
Adult female Xenopus laevis frogs were purchased from NASCO (Fort Atkinson, MI) and maintained under controlled light conditions at a water temperature of 18°C. The use of frogs as described was approved by the Institutional Committee for Animal Research. Oocytes were surgically collected from animals anesthetized by 0.17% tricaine immersion, incubated for 1 h with vigorous shaking in Values are means Ϯ SE. WNK3, with-no-lysine kinase 3; SLC12, solute carrier family 12; NKCC, Na ϩ -K ϩ -coupled chloride cotransporter; NCC, Na ϩ -coupled chloride cotransporter; KCC, K ϩ -coupled chloride cotransporter; NA, not assessed. a Ca 2ϩ -free ND96 medium (in mM: 96 NaCl, 2 KCl, 1 MgCl2, and 5 HEPES/Tris, pH 7.4, plus 2 mg/ml collagenase A), washed four times in regular ND96, defolliculated by hand, and incubated overnight in ND96 at 16°C. On the next day, mature oocytes were injected with 50 nl of water or with water containing 0.1-0.4 g/l of cRNA transcribed in vitro from the various constructs. Oocytes were incubated for 2-3 days before transport assays in ND96 at 16°C supplemented with 2.5 mM sodium pyruvate and 5 mg/100 ml of gentamicin; this incubation medium was changed every 24 h. On the day of the experiment, oocytes were switched to Cl Ϫ -free ND96 (in mM: 96 Na ϩ isethionate, 2 K ϩ gluconate, 6 Ca 2ϩ gluconate, 1 Mg 2ϩ gluconate, 5 HEPES/Tris, 2.5 sodium pyruvate, and 5 mg/100 ml gentamicin, pH 7.4) 2 h before the uptake assay.
Functional Assays with Cation/Cl
Ϫ Cotransporters
Xenopus laevis oocytes were injected with cRNA of NCC, NKCC1, NKCC2, KCC1, KCC2a, KCC2b, KCC3a, KCC3b, or KCC4 alone or together with cRNA of wild-type or kinase-dead WNK3 isoforms. After 2-3 days of incubation, metolazone-sensitive 22 Na ϩ (for NCC), bumetanide-sensitive 86 Rb ϩ (for NKCC1 and NKCC2), or Cl Ϫ -dependent 86 Rb ϩ uptake (for KCCs) was determined following our standard procedures (1, 2, 17, 20) . In brief, NCC measurements were performed under isotonic conditions. NKCC1 and NKCC2 uptake experiments were done in two different osmolar conditions: hypotonicity (160 mosM/kgH2O) and hypertonicity (260 mosM/kgH2O) for inhibition and activation of the cotransporters, respectively. KCC activity was also performed in two different conditions: hypotonicity (110 mosM/kgH2O) and isotonicity (200 mosM/kgH2O) for activation and inhibition, respectively. Sucrose was used to increase the osmolarity of the solutions while maintaining ionic strength and ion concentrations (see below).
Throughout the experiments, ouabain was used to inhibit the Na ϩ -K ϩ -ATPase, amiloride to block the Na ϩ channels, bumetanide to prevent activity of the Na ϩ -K ϩ -2Cl Ϫ cotransporter, and metolazone to inhibit the Na ϩ -Cl Ϫ cotransporter. The desired concentration of the inhibitor was present during both the incubation and uptake periods, except when noted.
Bumetanide-sensitive 86 Rb ϩ uptake assays. Bumetanide-sensitive 86 Rb ϩ uptake assays were used to measure the activity of Na ϩ -K ϩ - Fig. 3 . Effects of wild-type WNK3 variants on the activities of K ϩ -coupled chloride cotransporter KCC1 (A) KCC2b (B), KCC3a (C), and KCC4 (D). Experiments were performed in hypotonic conditions. KCC cRNAs were injected alone or together with each of the WNK3 variant cRNAs, as indicated. *P Ͻ 0.001 vs. control. Fig. 2 . Effects of wild-type WNK3 variants on the activities of Na ϩ -K ϩ -coupled chloride cotransporter (NKCC1; A) and Na ϩ -coupled chloride cotransporter (NCC; B). For this and the rest of the figures, basal activity in the absence of WNK3 was taken as 100%, and all data were normalized accordingly. Experiments for NKCC1 were performed in hypotonic conditions, hence, the very low activity in the control conditions. NKCC1-or NCC-expressing oocytes were coinjected with each of the WNK3 variant cRNAs, as indicated. *P Ͻ 0.001 vs. control (Ctrl). 4 , and 210 mosM/kgH2O) supplemented with 1 mM ouabain, 0.1 mM amiloride, and 0.1 mM bumetanide was followed by a 60-min uptake period in a K ϩ -free medium (in mM: 40 NaCl, 56 N-methyl-D-glucamine-chloride, 1.8 CaCl2, 1 MgCl2, 5 HEPES/Tris, pH 7.4, and 210 mosM/kgH2O) containing 1 mM ouabain, 0.1 mM amiloride, and 0.1 mM bumetanide plus 2 Ci of 22 Na ϩ /ml. To determine the 22 Na ϩ uptake due to NCC, parallel groups of oocytes were exposed to the same uptake medium, but in the presence of 0.1 mM metolazone. 86 Rb ϩ uptake due to the KCCs was determined by exposing groups of oocytes to Cl Ϫ -free uptake medium in which Cl Ϫ was substituted with gluconate. All uptake measurements were performed at 32°C. At the end of the uptake period, oocytes were washed three times in ice-cold uptake solution without isotope to remove extracellular fluid tracer. Oocytes were dissolved in 10% SDS, and tracer activity was determined for each oocyte by ␤-scintillation counting. All uptake experiments were performed at least three times and included at least 10 oocytes in each experimental group; statistical significance was defined as two-tailed P Ͻ 0.05, and results are reported as means Ϯ SE. The uptake observed in control groups was taken as 100%, and experimental groups were normalized accordingly. The significance of the differences between groups was tested by one-way ANOVA with multiple comparisons using Bonferroni corrections.
RESULTS AND DISCUSSION
Effects of WNK3 Variants on the Sodium-Coupled Chloride Cotransporters
We have previously shown that WNK3-18a is a potent activator of all three sodium-coupled chloride cotransporters: NKCC1 (9), NKCC2, and NCC (21) . The activation of NCC by WNK3-18a has been corroborated by other groups (7, 32) . In the present study, we tested the effects of all potential WNK3 variants on the activity of these cotransporters. For NKCC1, we performed the experiments using hypotonic conditions, in which this cotransporter is maximally inhibited (9) . Three experiments were performed for each of the WNK3 isoforms= effects on NKCC1. The bumetanide-sensitive basal uptake for NKCC1 in control conditions and in the presence of each of the WNK3 variants are depicted in Table 1 . While the Fig. 2A , the percentage increase for NKCC1 in the presence of WNK3-18a was 2,330 Ϯ 255, of WNK3-18b was 3,383 Ϯ 244, of WNK3-18aϩ22 was 3,320 Ϯ 405, and of WNK3-18bϩ22 was 2,217 Ϯ 567. Although WNK3-18bϩ22 was the variant that induced the weakest activation of NKCC1, it still increased activity by 1,500% when compared with control.
A similar situation occurred for NCC activation by the WNK3 variants. At least three experiments were performed for NCC with each of the WNK3 constructs. Table 1 shows the thiazide-sensitive 22 Na ϩ uptake obtained in experiments using each isoform. As shown in Fig. 2B , the activity of NCC was significantly increased by any isoform. The NCC activity was increased to 337 Ϯ 21%, 209 Ϯ 21%, 234 Ϯ 30%, and 208 Ϯ 19% by WNK3 variants 18a, 18b, 18aϩ22, and 18bϩ22, respectively. Note that isoform WNK3-18bϩ22, previously suggested to inhibit the activity of NCC (7), induced a similar level of activation as the other variants. Finally, we tested the effects of isoforms WNK3-18a and WNK3-18b on the 86 Rb ϩ uptake induced by NKCC2 in Xenopus laevis oocytes under hypotonic conditions. As shown in Table 1 , similar to the observations for NKCC1, WNK3-18a or WNK3-18b significantly increased the activity of NKCC2. There is no clear explanation for the discrepancies between our observations with WNK3-18b or WNK318bϩ22 and NCC and those of Glover et al. (7) . WNKs are complex kinases that are still poorly understood, but it seems that minimal disruption of their primary structures can prevent or switch their mode of action toward a particular target (13, 23, 29, 32) . For instance, although the effect of WNK3-18a on NCC is clearly dependent on its kinase activity, Yang et al. (32) have shown that a similar effect can be obtained by the WNK3 carboxyl terminal domain in the complete absence of the kinase domain. For this reason, all WNK variants used in this study were completely sequenced to avoid any unwanted mutations that could result in truncated or altered proteins. In addition, our data on WNK3-18b activation of NCC are fully supported by the fact that we observed the corresponding behavior of this variant toward NKCC1 and all other members of the SLC12A family (see below). Thus, our data reveal that WNK3 is a potent activator of the sodium-coupled chloride cotransporters of the SLC12A family, regardless of the type of exon 18 and/or of the presence or absence of exon 22.
Effects of WNK3 Variants on the Potassium-Coupled Chloride Cotransporters
We have previously observed that WNK3-18a is a powerful inhibitor of all four K ϩ -Cl Ϫ cotransporters, even when oocytes are incubated in hypotonic conditions in which KCCs are maximally activated (2, 9, 10) . In the present study, we analyzed the effects of the four WNK3 variants on all KCCs in simultaneous experiments, including the two known variants of KCC2 and KCC3. The chloride-dependent 86 Rb ϩ uptake for each group, in the absence or presence of WNK3 isoforms, is shown in Table 1 . Consistent with our conclusion that WNK3 isoforms activate all sodium-coupled chloride cotransporters, we observed that when coinjected in Xenopus laevis oocytes, all four WNK3 isoforms induced a significant decrease of KCC activity. As shown in Fig. 3 , the percentage of KCC inhibition varied between 60 and 90%. The weakest effect was observed for WNK3-18aϩ22 on KCC1, in which the degree of inhibition was ϳ50%. Thus, the type of exon 18 or the absence or presence of the exon 22 sequence does not affect the inhibitory effect of WNK3 on the K ϩ -Cl Ϫ cotransporters. 
Effects of the Catalytically Inactive WNK3 Variants on the Cation-Coupled Chloride Cotransporters
Elimination of the catalytic activity of WNK3 by substituting aspartate 294 to alanine within the kinase domain (WNK3-D294) has interesting consequences on the effects of WNK3 on SLC12 family members. We have shown using WNK3-18a that the D294A substitution not only prevents the positive or negative effects of WNK3 on NKCCs or KCCs, respectively, but completely reverses these effects of WNK3 (2, 9, 20, 21) . In the present study, we assessed the consequences of eliminating the catalytic activity in all WNK3 isoforms on their effects on the cotransporters. As shown in Table 2 and Fig. 4A 
·h
Ϫ1 by WNK3-18aϩ22 (P Ͻ 0.001); and 3,440 Ϯ 166 pmol·oocyte Ϫ1 ·h Ϫ1 by WNK3-18bϩ22 (P Ͻ 0.001). Thus, even in conditions that normally maximally increase the activity of the NKCC1 cotransporter, any of the WNK3-D294A isoforms was able to reduce its function. Similar observations were made for NCC (Fig. 4B) . The basal activity of NCC in isotonic conditions was decreased by all WNK3-D294A isoforms, although the weakest effect was observed with WNK3-18b. Figure 5 depicts the effects of WNK3-D294A isoforms on all four K ϩ -Cl Ϫ cotransporters. As shown before (2, 9, 10), elimination of the catalytic activity in WNK3-18a or WNK3-18b resulted in significant activation of the KCCs in isotonic conditions. When expressed in Xenopus laevis oocytes under isotonic conditions, KCCs are usually completely inactive [with the exception of a slight basal activity of KCC2 (24)], and KCC activation due to exposure of cells to hypotonicity is caused by dephosphorylation of the cotransporter (22) . Our observation that catalytically inactive WNK3 activates the KCCs in isotonic conditions strongly suggests that the presence of the inactive kinase dephosphorylates the KCCs, thus activating them. Evidence suggests that this involves protein phosphatases 1 and/or 2B (2). Interestingly, this is the only effect of WNK3 variants in which we found a difference between isoforms because, as shown in Fig. 5 , the presence of exon 22 precluded the activation of the KCCs by the catalytically inactive WNK3-D294A variants.
Although all WNK3 variants increased the activity of NKCC1 or NCC, it is worth notice that the degree of the effect is different among isoforms and cotransporters. Figure 6 illustrates this issue. In the absence of exon 22, it is evident that wild type and catalytically inactive isoforms 18a and 18b exhibits opposite pattern when NKCC1 and NCC are compared. For NKCC1, the activating effect of WNK3-18b or the inhibitory effect of its catalytically inactive version was significantly higher than corresponding 18a variants (Fig.  6A) . In contrast, in the case of NCC, the 18a variants were higher than the 18b isoforms (Fig. 6B) . Interestingly, these differences are changed or eliminated by the presence of exon 22. In the case of NKCC1, the presence of exon 22 makes more prominent the effect of the variant 18a than 18b (with or without catalytic activity), while the differences observed for NCC, in the absence of exon 22, disappeared in its presence. These observations suggest that sequences within WNK3 can enhance or decrease the interaction with the cotransporters, which could end up in modulating the degree of the final effect. The relevance of this behavior will depend on the expression of each isoform in the cell of interest. For instance, the differences observed for NKCC1 could be of relevance since this cotransporter is present in CNS where both WNK3-18a and WNK3-18b, as well as the exon 22 variants, are expressed (8) .
Taken together, the data from Tables 1 and 2 and Figs. 2 through 5 clearly show that all WNK3 isoforms are potent regulators of all members of the SLC12A family, and as such, WNK3 bypasses the tonicity requirements for the cotransporter's activation/inhibition. When NKCC1 or KCCs should be maximally active (hypertonicity and hypotonicity, respectively) the presence of the inactive WNK3s for NKCC1 and the wild-type WNK3s for KCCs results in almost complete inhibition of the cotransporters. In contrast, under conditions in which NKCC1 or KCCs are maximally inhibited (hypotonicity and isotonicity, respectively), the presence of wild-type WNK3s for NKCC1 and inactive WNK3s for KCCs results in activation of the cotransporters. For these reasons, we have proposed that WNK3 could be a cell volume-regulated kinase that, by modulating the activities of the cation-coupled chloride cotransporters, permits the appropriate response to a change in the osmolar environment.
WNKs have been proposed to have many functions besides the modulation of electroneutral cation-coupled chloride cotransporters, including regulating basic cellular processes such as mitosis (25) , apoptosis (27) and neoplastic transformation (19) , regulating synaptagmin 2 (15) , and interacting with many other kinases, like TGF-␤ (14), MAP kinases (31) , and the STE20-related alanine/proline-rich kinases SPAK and OSR1 (28) (for an excellent review, see Ref. 16 ). Thus, there are several possibilities for functional differences among WNK3 isoforms besides their effects on the SLC12 transporters that should be explored.
